T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2024 report and make more profitable business decisions.
T-cell acute lymphoblastic leukemia (T-ALL) is a type of blood cancer that affects T-cell lymphocytes, a type of white blood cell involved in the immune system’s function. T-ALL originates from immature T-cells in the bone marrow that fail to mature into normal functioning T-cells. These abnormal cells grow rapidly, crowding out normal blood cells (red blood cells, white blood cells, and platelets) in the bone marrow. T-ALL is more prevalent in children and adolescents than in adults. It accounts for approximately 15% of pediatric acute lymphoblastic leukemia (ALL) cases. The exact cause of T-ALL is not fully understood. However, certain risk factors have been identified, including genetic factors, exposure to high levels of radiation or certain chemicals, and certain genetic disorders or inherited syndromes.
The T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) drugs in development market research report provide comprehensive information on the therapeutics under development for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 69 molecules, with 53 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAdienne Pharma & Biotech SA
Affiliated Hospital of Xuzhou Medical University
Allterum Therapeutics LLC
Alpha Biopharma Inc
Arch Oncology Inc
Ascentawits Pharmaceuticals Ltd
AVM Biotechnology LLC
Ayala Pharmaceuticals Inc.
Bambino Gesu Hospital and Research Institute
Baylor College of Medicine
Beam Therapeutics Inc
Beijing Boren Hospital
Bioceltech Therapeutics Ltd
Cellestia Biotech AG
Changzhou Qianhong Bio-Pharma Co Ltd
Chengdu Zenitar Biomedical Technology Co Ltd
Enzyme by Design Inc
Gracell Biotechnologies Inc
Great Ormond Street Hospital for Children NHS Trust
Guangzhou Bio-gene Technology Co Ltd
Hebei Senlang Biotechnology Co Ltd
Houston Methodist Research Institute
iCell Gene Therapeutics LLC
Ichnos Sciences Inc
InnoCure Therapeutics Inc
Integra Therapeutics SL
Jazz Pharmaceuticals Plc
Johnson & Johnson
March Biosciences
MediSix Therapeutics Pte Ltd
MedPacto Inc
Mito BioPharm LLC
Nanjing Bioheng Biotech Co Ltd
National University of Singapore
OBI Pharma Inc
OneChain Immunotherapeutics
Oslo University Hospital
PersonGen BioTherapeutics (Suzhou) Co Ltd
PharmaEssentia Corp
Puretech Health Plc
Sareum Holdings Plc
SciTech Development LLC
Shenzhen Chipscreen Biosciences Co Ltd
Shenzhen Pregene Biopharma Co Ltd
Shenzhen University General Hospital
Sorrento Therapeutics Inc
St. Jude Children’s Research Hospital Inc
SunRock Biopharma SL
Suzhou Fundamenta Therapeutics Co Ltd
Takeda Pharmaceutical Co Ltd
Vincerx Pharma Inc
Wugen Inc
Xencor Inc
Xuanwu Hospital Capital Medical University
Zentalis Pharmaceuticals Inc
Zhejiang University
Table of Contents
Table
Figures
Frequently asked questions